About NOXXON
NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a combination trial with an anti-PD-1 immuno-oncology checkpoint inhibitor in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020; based on the trial results including overall survival and safety profile further studies are being planned in pancreatic cancer. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. A trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit from standard chemotherapy has delivered preliminary data from the first cohort showing consistent tumor reductions. The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic in 2021. NOXXON plans to develop NOX-E36 in patients with solid tumors.
|
Press ReleaseBerlin, Germany
2021, February 15 06:00 p.m. NOXXON enrolls first patient in the high dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer 2021, February 08 06:00 p.m. NOXXON appoints leading pancreatic cancer experts to Scientific Advisory Board 2021, February 01 06:00 p.m. NOXXON appoints experienced cancer drug developer Dr. Jose Saro as chair of Scientific Advisory Board |
EventsEuropean Life Sciences CEO Forum
Aram Mangasarian |